Our goal is to discover and develop novel, first-in-class medicines for patients suffering from 1) the most aggressive forms of cancer with currently limited treatment options, and 2) psychiatric disorders that are poorly addressed by current medications, including addiction and treatment resistant depression. Our innovative technology platform allows for exploiting inadequately served targets that require a highly adaptive and  specialized approach to drug discovery. With our deep understanding in target biology, combined with extremely tailored, cutting-edge discovery technologies, we envision to find novel cures.